by ComplianceQuest

Inspection Tracker

Tracker Overview Enforcement Themes Form 483s Warning Letters Inspections Recalls Investigators Companies Facilities

FDA Guidance Global Templates

Start with a Free ConsultationBook 30 minutes with a ComplianceQuest specialist.Book a Call

Sign In Create a Free Account

Big News: FDA is moving from MasterControl to ComplianceQuest.See Why

Search AgentQ/

Talk to a Specialist

Loading…

My DashboardInspection TrackerWarning LettersMantroForce

All Warning Letters

MantroForce

Warning LetterOpen

Room 701, Unit 127, 7/F Tower B New Mandarin Plaza Tsim Sha Tsui Hong Kong SAR ChinaIssued Jun 17, 2026Center for Drug Evaluation and Research (CDER)

Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy.

Violations1

Issue DateJun 17, 2026

Product TypeDrugs

StatusOpen

Letter Details

Firm: MantroForce
Location: Room 701, Unit 127, 7/F Tower B New Mandarin Plaza Tsim Sha Tsui Hong Kong SAR China
FEI Number: N/A
Country: China
Issue Date: June 17, 2026
Issuing Office: Center for Drug Evaluation and Research (CDER)
Product Type: Drugs
Status: Open

Subject

Unapproved New Drugs/Misbranded

MantroForce FDA Warning Letter, June 17, 2026